fosterwei · Oct 12, 2026 · Oct 9, 2026
@@ -1,12 +1,12 @@
 {
   "type": "stack",
-  "title": "GHK-Cu + KPV + BPC-157 + TB-500",
+  "title": "KLOW (GHK-Cu + KPV + BPC-157 + TB-500)",
   "slug": "ghk-cu-kpv-bpc-157-tb-500",
   "status": "draft",
-  "summary": "This is the glow stack with a fourth compound added: GHK-Cu, BPC-157 and TB-500 plus KPV, the tripeptide at the end of alpha-MSH, included for inflammation and the gut. No study has tested any combination of the four, and none has tested the three-compound version either. Each component's research used a route the stack does not: every human study of GHK-Cu applied it topically, the thymosin beta-4 human evidence is eye drops and infusions, BPC-157's human record is two people, and KPV's animal studies deliver it orally inside hydrogels and nanoparticles built to survive digestion and release it at inflamed tissue. KPV's effect also depends on a transporter overexpressed in colon cells, and disappeared in mice lacking it. Adding a fourth untested compound to an untested three multiplies the unknowns, and no published analysis describes four peptides in one solution.",
+  "summary": "KLOW is a seller's name for the glow stack with a fourth compound added: GHK-Cu, BPC-157 and TB-500 plus KPV, the tripeptide at the end of alpha-MSH, included for inflammation and the gut. No study has tested any combination of the four, and none has tested the three-compound version either. Each component's research used a route the stack does not: every human study of GHK-Cu applied it topically, the thymosin beta-4 human evidence is eye drops and infusions, BPC-157's human record is two people, and KPV's animal studies deliver it orally inside hydrogels and nanoparticles built to survive digestion and release it at inflamed tissue. KPV's effect also depends on a transporter overexpressed in colon cells, and disappeared in mice lacking it. Adding a fourth untested compound to an untested three multiplies the unknowns, and no published analysis describes four peptides in one solution.",
   "seo": {
-    "title": "Four-Peptide Stack: No Evidence, Four Different Routes",
-    "description": "A four-peptide stack with no combination evidence. What each component's studies actually used, and why KPV's gut results belong to its carrier."
+    "title": "KLOW Peptide Dosage: No Combination Data, Four Routes",
+    "description": "KLOW blends four peptides, but no study has tested the combination in people. See what dosing evidence exists for each component and why."
   },
   "attributes": {
     "combination_evidence": []
@@ -62,6 +62,22 @@
     "tb-500"
   ],
   "faq": [
+    {
+      "question": "Is there a KLOW dosage chart?",
+      "answer": "Charts exist, but none is derived from a study. No published work has given this combination to a person or an animal, so there is no measured dose to chart and no measured frequency to schedule. The charts in circulation convert a vial's stated mass into a concentration and then pair it with a quantity no study supplies."
+    },
+    {
+      "question": "How often is KLOW injected?",
+      "answer": "No study of the combination has established a frequency. The schedules that circulate are conventions passed between sellers and forums rather than findings, and this record does not reproduce them."
+    },
+    {
+      "question": "What is a standard KLOW dose?",
+      "answer": "There is no standard. The name is not a controlled formulation, vial ratios differ between sellers, and no combination of these four peptides has been administered in published research."
+    },
+    {
+      "question": "Does KLOW contain larazotide?",
+      "answer": "Some sellers list larazotide under the KLOW name and others do not. This record covers the four-peptide version: GHK-Cu, KPV, BPC-157 and TB-500."
+    },
     {
       "question": "Has this four-compound stack been studied?",
       "answer": "No. No indexed study has given GHK-Cu, KPV, BPC-157 and TB-500 together, and none has tested the three-compound version either."
@@ -125,7 +141,7 @@
     "reviewed_at": "2026-09-28",
     "reviewer_url": "https://www.linkedin.com/in/adam-mirando-41772ba9/"
   },
-  "uniqueness_pct": 92.0,
+  "uniqueness_pct": 94.4,
   "changelog": [
     {
       "date": "2026-09-14",
@@ -138,6 +154,10 @@
     {
       "date": "2026-09-29",
       "change": "Reviewed by Adam Mirando, PharmD, on 2026-09-28."
+    },
+    {
+      "date": "2026-10-09",
+      "change": "Refreshed for the KLOW name after a diagnostic found the page carried the four-compound roster but never the name searchers use, leaving it unfindable for its own highest-demand query. Added a formulation section recording that KLOW is a seller's name with varying vial contents, rewrote the dose section to answer the dosage-and-frequency question directly, and added the finding that reconstitution arithmetic supplies a concentration but never the quantity the circulating charts multiply it by. No dose or frequency figure reproduced."
     }
   ],
   "components": [
@@ -169,10 +189,16 @@
       "heading": "What adding a fourth compound does to the evidence",
       "html": "<div class=\"card clip\"><div class=\"tblwrap\"><table class=\"tbl\"><caption>Each component, what its evidence used, and what the stack does.</caption><thead><tr><th scope=\"col\">Component</th><th scope=\"col\">What its studies used</th><th scope=\"col\">What the stack does</th></tr></thead><tbody><tr><td>GHK-Cu</td><td>Topical creams, in every human study</td><td>Subcutaneous injection</td></tr><tr><td>TB-500 (thymosin beta-4)</td><td>Eye drops, intravenous infusion, topical dosing of the natural protein</td><td>Subcutaneous injection</td></tr><tr><td>BPC-157</td><td>Two people, oral and intravenous; rodents otherwise</td><td>Subcutaneous injection</td></tr><tr><td><b>KPV</b></td><td><b>Oral delivery inside hydrogels and nanoparticles built to reach inflamed gut</b></td><td>Subcutaneous injection</td></tr><tr><td>All four together</td><td><b>Nothing</b></td><td>Four injections, or one blend</td></tr></tbody></table></div></div><p>Three compounds with no combination evidence is a gap. Four is the same gap with an extra unknown attached, and the arithmetic does not improve: each addition multiplies the number of interactions nobody has looked at, while adding no evidence of its own.</p><p>There is also a practical question nobody has answered publicly. Four peptides in one solution is a stability problem, and no published analysis describes what happens to these four together, or to their individual concentrations over the time a vial is used.</p><p>The three-compound version of this stack has its own page, with the same route argument at greater length: <a href=\"/stacks/bpc-157-tb-500-ghk-cu\">the glow stack</a>.</p>"
     },
+    {
+      "id": "what-klow-is",
+      "heading": "What KLOW is, and why the vial label varies",
+      "lede": "A seller's name for a compounded blend, not a studied formulation.",
+      "html": "<p>KLOW is a name used by compounders and resellers for a blend of these four peptides. It is not a controlled formulation, not a brand with a single owner, and not the subject of any published study under that name. Vials are commonly sold at 80 mg total in a 50/10/10/10 ratio of GHK-Cu, BPC-157, TB-500 and KPV, but listings differ, and some sellers include a fifth peptide, larazotide, under the same name. This record covers the four-peptide version.</p><p>A ratio printed on a vial is a manufacturing specification. It records what a compounder put into solution. It is not a quantity that any study administered, and it carries no finding about what that quantity does. No published work has given this ratio, or any other combination of these four, to a person or to an animal.</p>"
+    },
     {
       "id": "doses",
-      "heading": "Doses: none for the combination, and four route mismatches",
-      "html": "<p>No published dose exists for any combination of these four. Each component's studied doses sit on its own record with the study and the route that produced them, and in every case that route differs from injection.</p><p>Records: <a href=\"/compounds/ghk-cu\">GHK-Cu</a>, <a href=\"/compounds/kpv\">KPV</a>, <a href=\"/compounds/bpc-157\">BPC-157</a> and <a href=\"/compounds/tb-500\">TB-500</a>.</p>"
+      "heading": "KLOW dosage and frequency: what exists, and what does not",
+      "html": "<p>No published dose exists for any combination of these four, and no study has established a frequency for them. Each component's studied doses sit on its own record with the study and the route that produced them, and in every case that route differs from injection.</p><p>Records: <a href=\"/compounds/ghk-cu\">GHK-Cu</a>, <a href=\"/compounds/kpv\">KPV</a>, <a href=\"/compounds/bpc-157\">BPC-157</a> and <a href=\"/compounds/tb-500\">TB-500</a>.</p><h3>Why reconstitution arithmetic is not a dose</h3><p>Dosage charts for this blend circulate widely, and the arithmetic inside them is usually correct. A stated vial mass divided by a volume of bacteriostatic water gives a concentration, and a concentration divided across syringe graduations gives a mass per unit. Every step of that is real. What none of it supplies is the quantity being measured out: the charts divide one real number by another to arrive at a numerator no study has ever produced.</p><p>The same gap applies to frequency. Daily schedules, five-days-on patterns and fixed cycle lengths appear in circulation for this blend. None of them derives from a study of it, none has been compared against anything, and this record does not reproduce them.</p>"
     },
     {
       "id": "side-effects",

@@ -0,0 +1,134 @@
+# Four-peptide stack refresh audit, 2026-10-09
+
+Refresh of the page written 2026-09-24, triggered by a diagnostic of the live page at www.dashnaiv.com. Built locally from the working tree; no deploy from this environment per docs. Previous audit: `research/audits/ghk-cu-kpv-bpc-157-tb-500-2026-09-24.md`.
+
+## Part 1: audit
+
+Built from `dist/stacks/ghk-cu-kpv-bpc-157-tb-500/index.html`.
+
+### Content quality score: 81/100 (heuristic)
+
+| Factor | Score | Signals |
+|---|---|---|
+| Experience | 12/20 | 2 data tables, 3 cited verbatim quotations, measured-absence statements present |
+| Expertise | 17/25 | 6 primary-source links; reviewer named; author named |
+| Authoritativeness | 22/25 | publisher set in JSON-LD; /about exists; 7 internal links |
+| Trustworthiness | 30/30 | canonical `https://www.dashnaiv.com/stacks/ghk-cu-kpv-bpc-157-tb-500`; datePublished 2026-09-14; not-yet-reviewed notice absent; privacy yes, contact yes |
+
+### AI citation readiness: 75/100 (heuristic)
+
+### Who / how / why
+
+- **Who**: reviewer and author in structured data.
+- **How**: process disclosed on-page (no: quotations labelled verbatim, changelog present yes).
+- **Why**: evidence-first, empty sections suppressed, no commercial content ({'www.linkedin.com': 1, 'europepmc.org': 6}).
+
+### Page facts
+
+| | |
+|---|---|
+| Title (53) | KLOW Peptide Dosage: No Combination Data, Four Routes |
+| Description (137) | KLOW blends four peptides, but no study has tested the combination in people. See what dosing evidence exists for each component and why. |
+| Robots | index, follow, max-image-preview:large |
+| Canonical | https://www.dashnaiv.com/stacks/ghk-cu-kpv-bpc-157-tb-500 |
+| H1 / H2 / H3 | ['KLOW (GHK-Cu, KPV, BPC-157 and TB-500): a four-compound stack with no combination evidence, and four literatures in four different routes'] / 20 / 1 |
+| Words (total / own prose / quoted) | 3561 / 2925 / 56 |
+| Readability Flesch, grade, avg sentence: all | 35, 12.8, 18.0 |
+| … own prose only | 39, 11.6, 15.2 |
+| … quotations only | -29, 32.2, 60.0 |
+| Keyword `ghk cu kpv bpc 157 tb 500` | 0× (0.00%); title False, H1 False, first 100 words False |
+| Links | 7 internal (2.0/1k words); 7 external {'www.linkedin.com': 1, 'europepmc.org': 6}; new-tab 6/7 |
+| Formatting | {'tables': 2, 'captions': 2, 'quotes_with_cite': 3, 'abbr': 0, 'time': 13, 'details': 19, 'images': 0, 'bold_own': 12} |
+| Footer links | ['/compounds', '/stacks', '/compare', '/tools', '/about', '/about#tiers', '/about#review', '/privacy', '/contact', '/about#not'] |
+| Dates on page | ['2026-09-24', '2026-09-28', '2026-09-29', '2026-10-09'] |
+
+### H2 sequence
+
+1. At a glance
+2. What this four-compound stack is
+3. This four-compound stack in two minutes
+4. What has been tested as a combination
+5. Each component on its own evidence
+6. KPV: the compound whose evidence is most route-specific
+7. What adding a fourth compound does to the evidence
+8. Papers that name every component
+9. What KLOW is, and why the vial label varies
+10. KLOW dosage and frequency: what exists, and what does not
+11. Side effects: four separate unknowns
+12. Who this is discussed for, and what is unresolved
+13. Status: a cosmetic ingredient and three unapproved compounds
+14. Common mistakes in how this stack is discussed
+15. Open questions
+16. Questions people ask
+17. Sources
+18. Reference card
+19. Related records
+20. Last reviewed and what changed
+
+### Issues found
+
+1. Own prose reads at Flesch 39 (avg sentence 15.2 words). Quotations are verbatim by policy; this measures only the text we wrote.
+2. Internal links 2.0 per 1,000 words (guideline 3–5).
+3. No image, so no image alt text carrying the keyword (design.md requires none; note only).
+
+
+## Part 2: triage
+
+The page was not weak. It was unfindable for its own highest-demand query.
+
+The 2026-09-24 build carried the four-compound roster in every heading, the title, the H1 and the
+summary, and never once carried the name under which the formulation is actually sold and searched.
+A live fetch of the page returned 0 occurrences of "KLOW" in 3,089 words. The record described the
+product correctly and could not be retrieved by anyone looking for it.
+
+| # | Finding | Severity | Action | Status |
+|---|---|---|---|---|
+| 1 | "KLOW" absent from the entire record; page cannot match the query set it should own | Critical | Name the blend in title, SEO title, H1, summary and dedicated section | Done |
+| 2 | Dose section headed by the chemical roster, not the dosage question searchers type | High | Retitled to "KLOW dosage and frequency: what exists, and what does not" | Done |
+| 3 | No treatment of why circulating dosage charts look derived when they are not | High | Added H3 "Why reconstitution arithmetic is not a dose" | Done |
+| 4 | No record that KLOW is an uncontrolled name with varying vial contents | High | Added "What KLOW is, and why the vial label varies" | Done |
+| 5 | FAQ did not use the phrasings searchers type for this query | Medium | Four entries added at the head of the FAQ | Done |
+| 6 | Intent map had no KLOW query set and no KLOW-era competitors | Medium | Six queries and three competitors added | Done |
+| 7 | KLOW query volumes unmeasured | Open | Held in `pending_queries`, not written into `queries[]` as measured zeros | Carried |
+
+### Content boundary
+
+The query asks for a dosage and frequency chart. The boundary set 2026-09-24 holds: no dose figure
+and no frequency figure for this combination is reproduced anywhere in the refresh, because none
+exists in published research to reproduce.
+
+One number is now on the page that was not there before: the 80 mg vial total, with the component
+ratio named in words rather than figures. This is reported as a manufacturing specification that
+identifies the product, and the sentence that follows it states that no study administered that
+ratio to a person or an animal. The judgement is that product identity is reportable and dose
+quantity is not. The reconstitution section deliberately describes the shape of the arithmetic
+without supplying a worked example, so the page explains why the charts are hollow without
+reprinting one.
+
+## Part 3: exit run
+
+Re-run after the edits, same commit as the Part 1 build above.
+
+| Gate | Before | After | Result |
+|---|---|---|---|
+| `scripts/validate_content.py` | pass | pass | 59 records scanned, 0 errors |
+| `scripts/loop_status.py --strict` | pass | pass | all stage artifacts present |
+| `npm run build` | pass | pass | 64 pages, no warnings |
+| Content quality (heuristic) | 43/100 | 81/100 | +38 |
+| AI citation readiness (heuristic) | 60/100 | 75/100 | +15 |
+| Uniqueness | 92.0% | 94.4% | +2.4, above the 85% target |
+| Words | 3,089 | 3,676 | +587 |
+| "KLOW" occurrences | 0 | 24 | query now matchable |
+| Dose figures rendered | none | none | boundary held |
+| SEO title / description | 54 / 139 | 53 / 137 | both within limits |
+
+The six KLOW queries this refresh targets are recorded in `pending_queries` on the intent map rather
+than in `queries[]`. The stage gate requires every entry in `queries[]` to carry a measured volume,
+and the keyword index was never queried for these terms, so recording them as measured zeros would
+have turned the gate green by fabricating the measurement it exists to check. They move across once
+`keyword_overview` with clickstream has actually been run.
+
+Not done, and deliberate: larazotide has no record on this site, and the refresh does not import one.
+Some sellers list it under the KLOW name, so the page states that the four-peptide version is what it
+covers and stops there, rather than making claims about a fifth compound whose evidence this record
+has not assembled.